Myovant Sciences Ltd (NASDAQ:MYOV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Saturday.

According to Zacks, “Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. The company’s product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. “

Separately, Evercore ISI started coverage on shares of Myovant Sciences in a research report on Wednesday, August 16th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $18.20.

Shares of Myovant Sciences (MYOV) opened at 12.47 on Friday. Myovant Sciences has a 52-week low of $10.25 and a 52-week high of $14.27. The company’s 50 day moving average is $12.59 and its 200 day moving average is $12.15. The firm’s market cap is $758.72 million.

COPYRIGHT VIOLATION WARNING: “Myovant Sciences Ltd (MYOV) Lifted to Hold at Zacks Investment Research” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/16/myovant-sciences-ltd-myov-lifted-to-hold-at-zacks-investment-research-2.html.

Large investors have recently modified their holdings of the stock. Quantitative Systematic Strategies LLC purchased a new position in Myovant Sciences during the second quarter valued at approximately $165,000. Goldman Sachs Group Inc. purchased a new position in Myovant Sciences during the second quarter valued at approximately $174,000. Wells Fargo & Company MN grew its stake in Myovant Sciences by 331.9% during the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock valued at $194,000 after acquiring an additional 12,700 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Myovant Sciences by 36.3% during the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock valued at $279,000 after acquiring an additional 6,330 shares in the last quarter. Finally, Swiss National Bank purchased a new position in Myovant Sciences during the second quarter valued at approximately $294,000.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.